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Abstract 
Global health has been threatened by the COVID-19 pandemic, caused by the novel severe acute 
respiratory syndrome coronavirus (SARS-CoV-2)1. Although considered primarily a respiratory 
infection, many COVID-19 patients also suffer severe cardiovascular disease2-4. Improving patient 
care critically relies on understanding if cardiovascular pathology is caused directly by viral 
infection of cardiac cells or indirectly via systemic inflammation and/or coagulation 
abnormalities3,5-9. Here we examine the cardiac tropism of SARS-CoV-2 using human pluripotent 
stem cell-derived cardiomyocytes (hPSC-CMs) and three-dimensional engineered heart tissues 
(3D-EHTs). We observe that hPSC-CMs express the viral receptor ACE2 and other viral 
processing factors, and that SARS-CoV-2 readily infects and replicates within hPSC-CMs, 
resulting in rapid cell death. Moreover, infected hPSC-CMs show a progressive impairment in 
both electrophysiological and contractile properties. Thus, COVID-19-related cardiac symptoms 
likely result from a direct cardiotoxic effect of SARS-CoV-2. Long-term cardiac complications 
might be possible sequelae in patients who recover from this illness.  
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Main text 
With over 20 million people affected worldwide, the outbreak of SARS-CoV-2 has already left its 
permanent mark on human history1,10. Cardiovascular complications, including worsening of pre-
existing conditions and onset of new disorders, significantly contribute to the increasing mortality 
of COVID-19 patients, but the underlying mechanisms of cardiopathology are unclear2,11-13. Upon 
lung infection, the uncontrolled release of inflammatory cytokines, termed “cytokine storm”, could 
induce multi-organ damage, ultimately leading to organ failure and worsening of pre-existing 
cardiovascular disorders5,6,8,14. Moreover, COVID-19 is associated with coagulopathies, which 
also can induce heart damage3,5,7. Lastly, SARS-CoV-2 could directly mediate heart injury by 
entering cardiomyocytes via binding of the viral spike glycoprotein to its extracellular receptor, 
angiotensin I converting enzyme 2 (ACE2)9,15,16. An increasing number of reports have showed 
presence of SARS-CoV-2 genome in the heart and signs of viral myocarditis in COVID-19 infected 
individuals, including asymptomatic cases, indicating that SARS-CoV-2 could exhibit cardiac 
tropism and thus directly impair cardiac function17-20. Myocardial infarction, arrhythmias, and heart 
failure are the most common cardiovascular complications observed in COVID-19 patients12,21,22. 
In this study we used human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) and 
engineered human heart tissues as platforms to study SARS-CoV-2 cardiac biology23,24, to clarify 
the functional changes behind these COVID-19-related cardiovascular symptoms. 
The susceptibility to SARS-CoV-2 infection depends on the expression of the viral receptor 
ACE29,15,16. We found that ACE2 is transcriptionally upregulated during cardiac differentiation of 
both RUES2 embryonic stem cells-derived cardiomyocytes (hESC-CMs; Fig. 1a) and WTC11c 
induced pluripotent stem cells-derived cardiomyocytes (hiPSC-CMs; Supplementary Fig. 1a). 
Single-cell RNA-sequencing analysis detected ACE2 mRNA in ~9% of hESC-CMs, indicating low 
and/or transitory transcriptional activation (Fig. 1b). A larger fraction of cells expressed moderate 
to high levels of endosomal cysteine proteases CTSB (cathepsin B; ~71.0%) and CTSL 
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(cathepsin L; ~46.0%). Detection of these factors is relevant because they can cleave the spike 
glycoprotein and lead to endomembrane fusion-mediated release of SARS-CoV-2 genome inside 
the cytoplasm15,25,26. Importantly, these viral processing factors were often co-expressed with 
ACE2 (Supplementary Fig. 1b). Although viral entry also can be mediated by TMPRSS215, this 
transmembrane serine protease was not detectable in hESC-CMs (Supplementary Fig. 1c), as 
also reported for the adult human heart27. Thus, the ACE2-endosomal viral entry pathway may be 
the only route for virus entry in cardiomyocytes. Indeed, PIKFYVE, another endosomal viral 
processing factor, was also broadly expressed in hESC-CMs (Supplementary Fig. 1c)26. Despite 
the low levels of mRNA, ACE2 protein was strongly expressed in hPSC-CMs derived from multiple 
lines (RUES2 female hESCs, H7 female hESCs, and WTC11c male hiPSCs), reaching levels 
comparable to those of VERO cells, a primate kidney epithelial line with established SARS-CoV-
2 tropism (Fig. 1c)15. Collectively, we concluded that hPSC-CMs express proteins that render 
them susceptible to SARS-CoV-2 infection23,24. 
Since H7 and WTC11c-derived hPSC-CMs showed the highest levels of ACE2, we tested their 
functional susceptibility to SARS-CoV-2. For this, we incubated highly-pure hPSC-CMs (> 80%; 
Supplementary Fig. 2a) with SARS-CoV-2/Wa-1 strain at multiplicity of infection (MOI; i.e. the 
number of infectious viral particles per cell) of either 0.1 (requiring propagation of the virus within 
the cells and secondary infection of others) or 5 (aiming to infect all the cells at the same time). 
We observed marked and disseminated viral cytopathic effects in both H7 hESC-CMs and 
WTC11c hiPSC-CMs. These effects were accelerated at 5 MOI, as expected (Fig. 2a and 
Supplementary Fig. 2b). Most notably, cessation of beating and cell death started as early as at 
48 hours post infection (HPI) in both cell lines, with more pronounced effects for H7 
cardiomyocytes. Immunofluorescence staining of SARS-CoV-2 nucleocapsid protein revealed 
substantial presence of viral factors in the cytoplasm of both H7 hESC-CMs and WTC11c hiPSC-
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CMs (Fig. 2b and Supplementary Fig. 2c) confirming that hPSC-CMs can be infected directly by 
SARS-CoV-2. 
To investigate if hPSC-CMs are permissive to SARS-CoV-2 replication, we quantified extracellular 
viral particles and intracellular viral RNA (by plaque assay and RT-qPCR, respectively). The one-
step growth curve after 5 MOI infection indicated that significant viral replication occurred steadily 
from 24-72 HPI, followed by a precipitous decline as the cells died (Fig. 2c). With a multi-step 
growth curve in cells (0.1 MOI infection), we confirmed that SARS-CoV-2 replicated inside hPSC-
CMs (Fig. 2d), with a marked increase in viral particles and RNA at 48 and 72 HPI (at which point 
the experiment was stopped). In agreement with morphological observations, H7 cardiomyocytes 
were more permissive to SARS-CoV-2 replication than WTC11c (Figs. 2c-d and Supplementary 
Figs. 2d-e), perhaps as a reflection of genetic or epigenetic differences that deserve further study.  
Upon viral infection, pathogen-associated molecular patterns (PAMPs) initiate the early immune 
response via host pattern recognition receptors (PRRs). Once viruses uncoat, RIG-I-like receptors 
(RLRs) bind to the uncapped and double stranded viral RNA in the cytosol and trigger innate 
immune activation, leading to the production of type I and type III interferons and the interferon-
induced antiviral response28. We found an increase in interferon transcripts (INFB1 and IFNL) at 
48 and 72 HPI in both cell lines, with a stronger effect in the more sensitive H7 cardiomyocytes 
(Fig. 2e and Supplementary Fig. 2f). The interferon-stimulated genes IFIT1 and IFITM1 were also 
upregulated at the latest time points. These results indicate that SARS-CoV-2 induces innate 
immune activation and interferon response also in hPSC-CMs29. 
We next investigated whether SARS-CoV-2 infection impairs the function of hPSC-CMs. First, we 
evaluated electrophysiological properties of infected H7 hESC-CMs and WTC11c hiPSC-CMs 
using multi-electrode arrays (MEA) over a time course of 72 HPI at MOI of 0.1 and 5. Distinctly 
from our earlier experiments on hPSC-CM monolayers, in this context we did not observe obvious 
cell death in any of the conditions (Fig. 3a and Supplementary Fig. 3a). This outcome may reflect 
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a decreased efficiency of viral infection as hPSC-CMs are plated at high density to ensure robust 
assessment of physiologically relevant electrophysiological properties. Remarkably, even in the 
absence of mayor cytopathic effects, SARS-CoV-2 infection rapidly resulted in reduced beating 
rate, lower depolarization spike amplitude, and decreased electrical conduction velocity (Figs. 3b-
c and Supplementary Figs. 3b-c). In H7 hESC-CMs we also observed a time-dependent increase 
in the duration of the field potential (FPD) both in spontaneously beating and electrically paced 
cultures (Fig. 3d; similar measurements could not be reliably obtained from WTC11c hiPSC-CMs 
due to the limited amplitude of the repolarization wave after SARS-CoV-2 infection, 
Supplementary Fig. 3b). The FPD reflects the interval between membrane depolarization and 
repolarization, and as such represent an in vitro surrogate of the QT interval measured by an 
electrocardiogram. It is well known that prolongation of the QT interval is pro-arrhythmogenic30. 
Overall, abnormalities in the generation and propagation of electrical signals were significant even 
in the absence of substantial cell death, suggesting that SARS-CoV-2 infection in cardiomyocytes 
could directly create a substrate for arrhythmias. These properties of SARS-CoV-2 infection in 
cardiomyocytes could explain the high rate of arrhythmia (~14%) which has been observed in 
COVID-19 patients5. 
We then evaluated the contractile properties of hPSC-CMs using three-dimensional engineered 
heart tissues (3D-EHTs), following their contractile behavior through magnetic field sensing31 
(Figs. 4a-b). For these experiments we focused on WTC11c hiPSCs since 3D-EHTs from H7 
hESC-CMs proved to spontaneously beat at too high a frequency (> 2 Hz) to enable accurate 
measurements of contractile behavior (i.e. the tissue had a tetanic-like contraction with minimal 
relaxation between beats at this frequency). We infected 3D-EHTs from WTC11c hiPSC-CMs 
with 10 MOI (to facilitate infection within the non-vascularized, cell-dense tissue), and analyzed 
their contraction for a week. The maximal twitch force decreased as early as 72 HPI, and the 
contractions continued to subside to < 25% of original force at 144 HPI (Figs. 4c-d, and 
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Supplementary Videos 1 and 2). Overall, the significant impairment in the contractile properties 
of 3D-EHTs demonstrates that the mechanical function of cardiomyocytes is impacted by SARS-
CoV-2 infection, and this could contribute to whole-organ cardiac dysfunction in patients32. 
A rapidly increasing number of reports acknowledge cardiovascular involvement as a prevalent 
complication observed in COVID-19 patients, but discriminating between direct versus indirect 
effects is still an open challenge12,14,18,19. Our results provide important evidence that SARS-CoV-
2 has the ability to directly infect cardiomyocytes, to impair both their electrophysiological and 
contractile properties, and eventually to induce cell death. These results support the hypothesis 
that, independent of inflammation or coagulopathy, SARS-CoV-2 can cause direct functional heart 
damage.  
One limitation of this study is our reliance on hPSC-CMs, which are well-known for their functional 
immaturity33. Moreover, while the in vitro systems we used have been successfully leveraged to 
model electrophysiological and contractile alterations due to drugs or inherited mutations34,35, their 
application to modeling COVID-19 will require further validation. A recent report by Dolhnikoff et 
al. identified coronaviral particles in the cytoplasm of cardiomyocytes, endothelial cells, and 
fibroblasts by electron microscopy in the heart of an 11 year-old child who died from multi-system 
inflammatory syndrome in children (MIS-C) following COVID-19 infection20. This indicates that in 
vivo cardiomyocytes with substantially greater maturity than used here are susceptible to SARS-
CoV-2 infection. COVID-19 patients are commonly treated with steroids to control systemic 
inflammation. However, our data suggests that treatments aimed to control the direct damage of 
SARS-CoV-2, e.g. antiviral medications and/or cardioactive drugs, should also be taken into 
consideration to prevent long-term cardiovascular complications.  
(which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 
The copyright holder for this preprintthis version posted August 30, 2020. . https://doi.org/10.1101/2020.08.30.274464doi: bioRxiv preprint 
 8 
Methods 
Cell culture. Undifferentiated RUES2 hESCs (RUESe002-A; WiCell) and WTC11c hiPSCs (a gift 
of Dr. Bruce Conklin, Gladstone Institutes, San Francisco) were maintained in mTeSR1 (Stemcell 
Technologies) on tissue culture dishes coated with Matrigel (Corning) at 0.17 mg/mL, and 
passaged as small clumps using Versene (Gibco). Cardiomyocytes from RUES2 and WTC11c 
were differentiated as previously described36. Briefly, undifferentiated cells were seeded at 1,000 
cells/cm2 in mTeSR1 supplemented with 10 µM Y-27632 (Tocris) on Matrigel-coated dishes. After 
24 h media was changed to mTeSR1 with 1 μM CHIR-99021 (Cayman). On day 0 mesoderm 
differentiation was induced with 3 μM CHIR-99021 in RPMI-1640 media (ThermoFisher) 
supplemented with 500 μg/mL BSA (Sigma-Aldrich) and 213 μg/mL ascorbic acid (Sigma-
Aldrich), denoted as RBA media. On day 2 media was changed to RBA containing 2 µM WNTC59 
(Selleckchem). On day 4 media was changed to plain RBA. On day 6 media was changed to 
RPMI-1640 plus B-27 supplement (ThermoFisher), with further media changes every other day. 
Heat-shock was performed on day 13 for 30 min at 42 °C, and on day 14 cardiomyocytes were 
dissociated and frozen in CS10 cryopreservation media (Sigma-Aldrich). H7 hESCs (WA07; 
WiCell) were differentiated in suspension culture format by collaborators at the Center for Applied 
Technology Development at the City of Hope in California (as previously described37), received 
by dry-ice shipment, and stored in liquid nitrogen before use. 
Flow cytometry. Cardiac differentiation efficiency was determined by flow cytometry in hPSC-
CMs fixed with 4% paraformaldehyde for 15 min at room temperature. Cells were centrifuged at 
300 g for 5 min and incubated at room temperature for 1 h with either APC-cTnT antibody (Miltenyi 
Biotech #130-120-543) or APC-IgG1 isotype control antibody (Miltenyi Biotech #130-120-709), 
both used at 1:100 dilution in DPBS (Gibco) with 5% fetal bovine serum (FBS) and 0.75% saponin. 
Following washes with DPBS with 5% FBS, samples were run on a BD FACSCanto II flow 
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cytometer and data from 10,000 valid events were acquired with the BD FACSDIVA software. 
Analysis was performed with FlowJo v10.7. 
RNA-seq. Bulk RNA-seq datasets from differentiating RUES2 hESC-CMs had been previously 
generated and analyzed36 (GEO dataset: GSE106688). 
Western blot. Cell pellets were incubated in RIPA Buffer supplemented with 1X Protease 
inhibitors (ThermoFisher) at 4 °C for 20 min. Samples were then centrifuged at 21,000 g for 15 
min at 4 °C, and protein concentration in the supernatant was quantified with BCAssay 
(ThermoFisher). 25 µg of protein were mixed with 1X non-reducing SDS sample buffer and 
incubated at 37 °C for 30 min. Samples were run on 4-20% mini-PROTEAN TGX precast gels 
(Bio-Rad) and then transferred on PVDF membranes. Membranes were incubated with 5% non-
fat dry milk in TBS buffer supplemented with 0.1% Tween-20 (blocking buffer) for 1 h at room 
temperature. Primary antibodies were incubated in blocking buffer for 2 h at room temperature 
(rabbit anti-ACE2 [Abcam #ab15348, used at 1:500 dilution]; mouse anti-GAPDH [Abcam 
#ab8245, used at 1:3,000 dilution]). Membranes were washed and further incubated with 
fluorescent dye-conjugated secondary antibodies for 1 h at room temperature (AlexaFluor 647 
goat anti-rabbit IgG1 and AlexaFluor 488 goat anti-mouse IgG1, both used at 1:1,000 dilution in 
blocking buffer) and fluorescent signals were acquired using with a GelDoc Imager (Bio-Rad). 
Single cell RNA-seq. A single cell suspension was generated from cultures of RUES2 hESC-
CMs at day 30 of differentiation, and single cell RNA-seq was performed using the Chromium 
NextGEM Single Cell 3’ kit (10X Genomics). 10,000 cells per condition were loaded on 
independent microfluidics channels to generate Gel bead-in-Emulsion (GEMs), which were 
further processed as per the manufacturer’s instructions to generate Illumina-compatible 
sequencing libraries. The sample was analyzed using two runs of high output NextSeq 500 with 
a 150 cycle kit, reading 28 base pairs for read 1 (barcode and UMI), 91 base pairs for read 2 (3’ 
end of cDNAs), and 7 base pairs for the i7 index. For data analysis, cellranger mkfastq was used 
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to transfer demultiplexed raw base call files into library-specific FASTQ files. The FASTQ files 
were separately mapped to the GRC38 human reference genome using STAR as a part of the 
cellranger pipeline. Gene expression counts were done using cellranger count based on Gencode 
v25 annotation, and cell identifiers and Unique Molecular Identifiers (UMI) were filtered and 
corrected with default setting. Raw cellranger count outputs was aggregated and visualized by a 
subsampling procedure using cellranger aggr. Downstream analysis was performed in the R 
package Seurat38,39. Filters were applied to eliminate cells with less than 1,000 genes detected, 
with over 40,000 UMIs, or with over 35% mitochondrial gene reads. Post filtering, cell-to-cell gene 
expression was normalized by total expression, multiplied by the scale factor of 10000, and the 
result is log-transformed [Log norm exp]). Data dimensionality reduction was done by principal 
component analysis on the top 2,000 most variable genes. The top 10 principal components (PCs) 
that explained most variance were selected, as confirmed by an Elbow plot. For visualization, 
UMAP dimensionality reduction for the top 10 PCs was performed to produce coordinates for cells 
in 2 dimensional space. The relative expression levels of genes of interest were plotted using the 
FeaturePlot function in Seurat. 
SARS-CoV-2 generation. All experiments using live virus were performed in the Biosafety Level 
3 (BSL-3) facility at the University of Washington in compliance with the BSL-3 laboratory safety 
protocols (CDC BMBL 5th ed.) and the recent CDC guidelines for handling SARS-CoV-2. Before 
removing samples from BSL-3 containment, samples were inactivated by Trizol or 4% 
paraformaldehyde, and the absence of viable SARS-CoV-2 was confirmed for each sample by 
plaque assays. SARS-Related Coronavirus 2, Isolate USA-WA1/2020 (SARS-CoV-2) was 
obtained from BEI Resources (NR-52281) and propagated in VERO cells (USAMRIID). Briefly, 
VERO cells were maintained in DMEM (Gibco) supplemented with 10% heat-inactivated FBS, 
100 U/mL penicillin, and 100 U/mL streptomycin at 37 °C in a 5% CO2 humidified incubator. To 
generate virus stock, cells were washed once with DPBS and infected with SARS-CoV-2 in 
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serum-free DMEM. After 1 h of virus adsorption, the inoculum was replaced with DMEM 
supplemented with 2% heat-inactivated FBS, and cells were incubated at 37 °C in a 5% CO2 
incubator until ~70% of cells manifested cytopathic effects. The virus was harvested by collecting 
the culture supernatant followed by centrifugation at 3,000 g for 15 min at 4 °C to remove the cell 
debris. Virus titer was then measured by plaque assay on VERO cells (as described below), and 
stocks were stored at -80°C. 
SARS-CoV-2 titering. Viral preparations and culture supernatant from SARS-CoV-2-infected 
cardiomyocytes were titered using a plaque assay. Briefly, 350,000 VERO cells were seeded in 
12-well plates and incubated for 1 h at 37 °C with 10-fold dilutions of virus-containing media. A 
solution of 1:1 1% agarose and 2X DMEM supplemented with 4% heat-inactivated FBS, L-
glutamine, 1X antibiotic-antimycotic (Gibco), and 220 mg/mL sodium pyruvate was layered on top 
of the cells, followed by incubation at 37 °C for 2 days. After fixing with 10% formaldehyde, the 
agarose layer was removed and cells were stained with 0.5% crystal violet solution in 20% 
ethanol. Plaques were counted, and the virus titer in the original sample was assessed as plaque-
formation unit per mL (PFU/mL). 
Viral infection. Cryopreserved hPSC-CMs were thawed and plated in RPMI-1640 supplemented 
with B-27, 5% FBS, and 10 µM Y-27632. After 24 h the media was replaced with RPMI-1640 
supplemented with B-27 only. After 3 days, cardiomyocytes were harvested with Versene 
supplemented with 0.5% Trypsin (Gibco) at 37 °C for 5 min to obtain single-cell suspensions. 
250,000 cardiomyocytes were seeded in Matrigel-coated 12-well plates in RPMI-1640 
supplemented with B-27, 5% FBS, and 10 µM Y-27632. The media was replaced with RPMI-1640 
supplemented with B-27 the next day, and then every other day for 1 week. SARS-CoV-2 was 
diluted to the desired MOI in DMEM and incubated on hPSC-CMs for 1 h at 37 °C (non-infected 
[mock] controls were incubated with DMEM only). Cells were then washed with DPBS and 
cultured in RPMI-1640 supplemented with B-27. 
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Immunofluorescence. 200,000 cardiomyocytes were plated on glass-bottom 24-well plate 
(CellVis) and infected as described above. Cells were fixed with 4% paraformaldehyde in DPBS 
for 30 min at room temperature and then washed 3 times with DPBS for 5 min. Cells were 
permeabilized using 0.25% Triton X-100 (Sigma-Aldrich) in DPBS and blocked for 1 h with 10% 
normal goat serum supplemented with 0.1% Tween-20 in DPBS. Primary antibodies were 
incubated overnight at 4 °C in DPBS with 1% normal goat serum and 0.1% Tween-20 (rabbit anti-
2019-nCoV NP [Sino Biological #40143-R019, used at 1:200 dilution]; and mouse anti-Sarcomeric 
α-actinin [Abcam ab# ab9465, used at 1:500 dilution]). Cell were washed three times with DPBS 
containing 0.2% Tween-20, and incubated for 1 h at room temperature with secondary antibodies 
diluted in DPBS supplemented with 1% BSA and 0.1% Tween-20 (AlexaFluor 594 goat anti-rabbit 
IgG1 and AlexaFluor 647 goat anti-mouse IgG1, both used at 1:1,000 dilution). DAPI (Sigma-
Aldrich) was diluted at 300 nM in water and incubated on the cells for 15 min at room temperature, 
followed by three washes in DPBS containing 0.2% Tween-20. Images were taken with a 40x oil 
objective on a Nikon Eclipse microscope with Yokogawa W1 spinning disk head, and formatted 
with Fiji software. 
Gene expression analysis and viral RNA detection. Infected cardiomyocytes were washed 
once with DPBS and incubated with 400 µL per well of Trizol reagent (Invitrogen) for 10 min at 
room temperature. Chloroform was added in a 5:1 ratio to Trizol, and samples were incubated at 
room temperature for 2 min. The aqueous phase was separated by centrifugation (21,000 g for 
15 min at 4 °C) and incubated with isopropanol (1:1 ratio) and 25 µg of Glycoblue (ThermoFisher) 
for 10 min at room temperature. RNA pellets were harvested by centrifugation (21,000 g for 15 
min at 4 °C), washed twice with 75% ethanol, and resuspended in nuclease-free water. cDNA 
was prepared with M-MLV reverse transcriptase according to the manufacturers’ instruction. 
Quantitative real-time reverse transcription PCR (RT-qPCR) was performed with SYBR Select 
Master Mix (Applied Biosystems) using 10 ng of cDNA and 400 nM forward and reverse primers 
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(Supplementary table 1). Reactions were run on a CFX384 Real-Time System (Bio-Rad), and 
data was analyzed using the ΔΔCt method using HPRT1 as the housekeeping gene. Primers 
were designed using PrimerBlast, and confirmed to amplify a single product. 
Electrophysiological analysis with MEA. Cryopreserved cardiomyocytes were thawed and 
cultured as described above. CytoView MEA 48- and 24-well plates (Axion BioSystems) were 
coated with 0.17 mg/mL of Matrigel for 1 h at 37 °C. 50,000 (48-well plate) or 100,000 (24-well 
plate) hPSC-CMs were resuspended in 6 µL or 10 µL, respectively, and plated on each MEA well, 
as previously described40. Media was changed with RPMI-1640 supplemented with B-27 every 
other day for 1 week. One the day of viral infection, cells were washed once with DPBS and 
incubated with 50 µL (48-well plate) or 100 µL (24-well plate) of SARS-CoV-2 suspension for 1 h 
at 37 °C. Media was replaced with RPMI-1640 supplemented with B-27, and the plate was 
transferred directly into Maestro Pro system (Axion BioSystems) and kept at 37 °C with 5% CO2 
for the duration of the experiment. Electrophysiological recordings were taken for 5 min at 
specified time points using Axis software version 2.0.4. (Axion BioSystems). Voltage was acquired 
simultaneously for all the electrodes at 12.5 kHz, with a low-pass digital filter of 2 kHz for noise 
reduction. The beat detection threshold was 100 µV, and the FPD detection used a polynomial 
regression algorithm with the threshold set at 1.5 × noise to detect repolarization waves. Pacing 
was performed at 2 Hz with an alternating square wave (± 1 V, 100 nA, 8.33 kHz) delivered 
through the dedicated stimulator in the Maestro Pro system to a selected electrode (not used for 
recording). Automated analysis was performed using Cardiac Analysis Software v3.1.8 (Axion 
BioSystems), which automatically computes the Fridericia correction to account for beat rate 
variability during FPD measurements [FPDc = FPD/(beat period)1/3]. 
Contractility analysis with 3D-EHTs. 3D-EHTs were generated from hPSC-CMs embedded 
with stromal cells in a 3D fibrin gel suspended between pairs of silicone posts, as previously 
described31. For each pair of silicone posts one was flexible and had a 1 mm3 magnet embedded 
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in its tip, and the other post was rendered rigid by embedding a 1.1 mm glass capillary tube. Each 
3D-EHT was casted in a mold made of 2% agarose by adding 500,000 WTC11c hiPSC-CMs and 
50,000 HS27a stromal cells in a fibrin gel solution (89 µL RPMI-1640 supplemented with B-27, 
5.5 µl of DMEM/F12, [Gibco], 2.5 µL of 200 mg/mL bovine fibrinogen [Sigma-Aldrich], and 3 µL of 
100 U/mL thrombin [Sigma-Aldrich]. The cell-gel mixture was incubated at 37 °C for 2 h to allow 
for fibrin polymerization. Afterwards, 3D-EHTs were transferred from the agarose molds to 24-
well tissue culture dishes containing 3D-EHT media (RPMI-1640 media supplemented with B-27 
and 5 mg/mL aminocaproic acid [Sigma-Aldrich]. Media was changed every other day for 2 weeks. 
For SARS-CoV-2 infection, 3D-EHTs were temporarily housed in 2% agarose molds, and 200 µL 
of viral solution in DMEM was used to infect each single tissue for 1 h at 37 °C (DMEM was used 
for mock controls). 3D-EHTs were then transferred in fresh 3D-EHT media for the rest of the 
experiment. Twitch force was recorded by tracking the movement of magnets embedded in the 
flexible posts, as previously described31. Briefly, we used a custom-built printed circuit board 
(PCB) containing giant magnetoresistive (GMR) sensors (NVE, Eden Prairie, MN) in a 
Wheatstone bridge configuration and relying on instrumentation amplifiers and operational 
amplifiers to filter out signal noise. 3D-EHTs in the 24-well dish were placed into a 3D-printed 
caddy that contained the PCB with GMR sensors such that the flexible, magnetic posts of 3D-
EHTs were directly above each GMR sensor. Data from the PCB was collected by LabView 
(National Instruments) on a laptop in the BSL-3 facility. The voltage traces from the magnetic 
sensors were analyzed for amplitude and frequency using a custom Matlab protocol. The 
amplitudes were then converted from voltage to twitch force using a characterization constant. 
Statistical analyses. Statistical analyses were performed using Prism 8.1.3 (GraphPad). The 
type and number of replicates, the statistics plotted, the statistical test used, and the test results 
are described in the figure legends.  
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Figures and figure legends 
 
Figure 1 - hPSC-CMs express SARS-CoV-2 receptors and processing factors. (a) RNA-seq 
during RUES2 hESC-CM differentiation. ACE2 is quantified as fragments per kilobase of 
transcript per million mapped reads (FPKM). Mean ± SEM of two independent experiments. ESC: 
embryonic stem cells (day 0); ME: mesoderm (day 2); CP: cardiac progenitors (day 5); CM: 
cardiomyocytes (day 14). Differences versus ESC by one-way ANOVA followed by Sidak 
correction for multiple comparisons (*** = p < 0.001). (b) sc-RNA-seq gene expression heatmaps 
from RUES2 hESC-CMs after dimensionality reduction through Uniform Manifold Approximation 
and Projection (UMAP). TNNT2 provides a pan-cardiomyocyte marker.  (c) Western blot for ACE2 
in hPSC-CMs from multiple lines. hPSCs: negative control; VERO cells: positive control. 
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Figure 2 - hPSC-CMs are permissive to SARS-CoV-2 infection and replication. (a) Cytopathic 
effects of SARS-CoV-2 at 5 MOI in H7 hESC-CMs and WTC11c hiPSC-CMs during a time course 
of 120 h. Scale bars: 100 µm. (b) Immunofluorescent staining of H7 hESC-CMs and WTC11c 
hiPSC-CMs at 48 HPI with SARS-CoV-2 dose of 0.1 MOI. Scale bars: 50 µm. Individual channels 
are shown in Supplementary Fig. 2c. (c) One-step viral growth curve in H7 hESC-CMs infected 
with SARS-CoV-2 at 5 MOI over a time course of 120 h. (d) Multi-step viral growth curve in H7 
hESC-CMs infected with SARS-CoV-2 at 0.1 MOI over a time course of 72 h. For both c and d, 
lines connect the means of two independent experiments. Viral RNA indicating intracellular viral 
replication is plotted on the left y axis as % of HPRT1. Viral particles secreted in the supernatant 
are plotted on the right y axis as PFU/mL. (e) RT-qPCR of interferon response genes in H7 hESC-
CMs infected with SARS-CoV-2 at 0.1 MOI. Mean ± SEM of 2 independent experiments. 
Differences versus non infected (mock) control by two-way ANOVA followed by Sidak correction 
for multiple comparisons (* = p <0.05; ** = p < 0.01).  
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Figure 3 - Electrophysiological alterations in hPSC-CMs infected with SARS-CoV-2. (a) 
Representative images of SARS-CoV-2-infected H7 hESC-CMs on MEA wells at 72 HPI. Scale 
bars: 50µm (b) Representative recordings of spontaneous electrical activity of SARS-CoV-2-
infected H7 hESC-CMs at 72 HPI. (c) Representative quantifications of electrophysiological 
properties from MEA analyses in SARS-CoV-2-infected H7 hESC-CMs. Mean ± SEM of 8 wells. 
Differences versus mock control by two-way ANOVA with Sidak correction for multiple 
comparisons (*** = p < 0.001). (d) Representative field potential traces in SARS-CoV-2-infected 
H7 hESC-CMs at 72 HPI, and quantification of field potential duration corrected by beat rate 
(FPDc) in spontaneous and paced experiments. Mean ± SEM of 8 and 6 wells for spontaneously 
beating and paced cells, respectively. Statistical analyses as for panel c (** = p < 0.01).  
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Figure 4 - Force production of 3D-EHTs made from hiPSC-CMs progressively declines 
during SARS-CoV-2 infection. (a) Schematic representation of the magnetic sensing system: 
the 3D-EHT is suspended between two posts (one rigid, one flexible). The magnet is localized 
inside the flexible post, and the post movement during 3D-EHT contraction is recorded by the 
sensor located at the bottom of the dish (converting displacement into voltage changes). (b) 
Representative picture of a 3D-EHT. Scale bar: 1 mm. (c) Representative time course analysis of 
twitch force in 3D-EHTs from WTC11c hiPSC-CMs after SARS-CoV-2 infection at 10 MOI. Data 
are shown as mean ± SEM for mock controls and 4 infected 3D-EHTs. Differences versus mock 
by two-way ANOVA with Sidak correction for multiple comparisons (* = p < 0.05). (d) 
Representative voltage traces at different time points. 
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